Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today)

Amgen Confirms GDNF Halt In Parkinson's Development

Feb. 14, 2005

By Jennifer Boggs

No Comments

Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today)

Vical Sets SPA, Readies For Allovectin-7 Phase III Trial

Feb. 11, 2005

By Jennifer Boggs

No Comments

Vical Sets SPA, Readies For Allovectin-7 Phase III Trial

Feb. 11, 2005

By Jennifer Boggs

No Comments

MediciNova Prices Japanese IPO, Gets $107M For Pipeline

Feb. 10, 2005

By Jennifer Boggs

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Articles by Jennifer Boggs

Vertex, Avalon Sign $73M Cancer Drug Agreement

Accentia Files For $86M IPO To Fund Trials, Pay Off Debt

ConjuChem Raises C$21.7M For Upcoming DAC Studies

ConjuChem Raises C$21.7M For Upcoming DAC Studies

Accentia Files For $86M IPO To Fund Trials, Pay Off Debt

Amgen Confirms GDNF Halt In Parkinson's Development

Amgen Confirms GDNF Halt In Parkinson's Development

Vical Sets SPA, Readies For Allovectin-7 Phase III Trial

Vical Sets SPA, Readies For Allovectin-7 Phase III Trial

MediciNova Prices Japanese IPO, Gets $107M For Pipeline

Today's news in brief

Today's news in brief

Enhanced Cognition: Lewy body dementia phase II pumps stock

Experimental mRNA gene therapy suppresses preeclampsia in mice

Probing bidirectional cancer-autoimmune link can yield new targets